Infliximab also exhibited significant therapeutic activity in the chronic UC model, but AAV8-TBG-siRT+B+I ameliorated the manifestations of chronic colitis and restored the expression of TNF-α, B7-1 and integrin α4 to a better extent than infliximab (Fig. 10c–l and Supplementary Figs. 20c–f, 21, 22, 23). This evidence concerns the gene CD80 and Chronic colitis.